×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
QGEN – qiagen n.v. common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
QGEN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
02:12 am
qgen
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth [Yahoo! Finance]
Low
Report
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth [Yahoo! Finance]
1/12
02:00 am
qgen
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
Low
Report
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
1/10
01:07 am
qgen
Qiagen (NYSE:QGEN) was downgraded by analysts at Wall Street Zen fro
Low
Report
Qiagen (NYSE:QGEN) was downgraded by analysts at Wall Street Zen fro
1/1
12:05 pm
qgen
Qiagen N.V. (NYSE:QGEN) is a favorite amongst institutional investors who own 82% [Yahoo! Finance]
Low
Report
Qiagen N.V. (NYSE:QGEN) is a favorite amongst institutional investors who own 82% [Yahoo! Finance]
12/30
04:14 pm
qgen
Qiagen (NYSE:QGEN) had its "hold (c)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Qiagen (NYSE:QGEN) had its "hold (c)" rating reaffirmed by analysts at Weiss Ratings.
12/21
01:08 am
qgen
Qiagen (NYSE:QGEN) was upgraded by analysts at Wall Street Zen from
Low
Report
Qiagen (NYSE:QGEN) was upgraded by analysts at Wall Street Zen from
12/19
07:49 am
qgen
Syndromic Multiplex Diagnostics Market Size to Hit USD 4.13 Billion by 2032, Growing at a CAGR of 4.71% - SNS Insider [Yahoo! Finance]
Low
Report
Syndromic Multiplex Diagnostics Market Size to Hit USD 4.13 Billion by 2032, Growing at a CAGR of 4.71% - SNS Insider [Yahoo! Finance]
12/18
12:04 pm
qgen
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million [Yahoo! Finance]
Low
Report
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2025
01:04 pm
qgen
qiagen n.v. common shares
BEAT
Report
-1.1%
qiagen n.v. common shares
8/5/2025
04:05 pm
qgen
qiagen n.v. common shares
IN-LINE
Report
-4.9%
qiagen n.v. common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/9
12:05 pm
qgen
Form 25-NSE/A QIAGEN N.V. Filed by: NEW YORK STOCK EXCHANGE LLC
Low
Report
Form 25-NSE/A QIAGEN N.V. Filed by: NEW YORK STOCK EXCHANGE LLC
1/8
09:50 am
qgen
Form 25-NSE QIAGEN N.V. Filed by: NEW YORK STOCK EXCHANGE LLC
Low
Report
Form 25-NSE QIAGEN N.V. Filed by: NEW YORK STOCK EXCHANGE LLC
12/22
06:02 am
qgen
Form 6-K QIAGEN N.V. For: Dec 31
Low
Report
Form 6-K QIAGEN N.V. For: Dec 31
11/12
09:34 am
qgen
Form SCHEDULE 13G/A QIAGEN N.V. Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SCHEDULE 13G/A QIAGEN N.V. Filed by: WELLINGTON MANAGEMENT GROUP LLP
11/6
06:04 am
qgen
Form 6-K QIAGEN N.V. For: Sep 30
Low
Report
Form 6-K QIAGEN N.V. For: Sep 30
11/6
06:04 am
qgen
Form 6-K QIAGEN N.V. For: Sep 30
Low
Report
Form 6-K QIAGEN N.V. For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/3
European shares rise 2% on stimulus hopes [Reuters]
16.8%
12/26 Qiagen NV (NYSE: QGEN) had its "underperform" rating re-affirmed by analysts at Bank of America Corp. They now have a $28.00 price target on the stock. 11.0%
11/15 QIAGEN Receives Several Conditional, Non-binding Indications of Interest, Enters Into Discussions to Explore Potential Strategic Alternatives 8.5%
11/13 Qiagen up 7% on rumored Thermo Fisher interest [Seeking Alpha] 6.2%
10/9 Qiagen NV (NYSE: QGEN) was downgraded by analysts at Kepler Capital Markets from a "hold" rating to a "reduce" rating. 5.4%
1/8 Calibre Scientific Acquires NeXtal Biotechnologies to Further Expand its Protein Portfolio 5.3%
2/4 Q4/2019 12/31/2019 EPS 0.480 ZacksConsensus 0.440 ActVsEst 0.040 - Beat 5.1%
11/6 QIAGEN Launches Novel NGS Workflow for Simultaneous DNA and RNA Analysis for Use in Cancer Profiling at 2019 AMP Annual Meeting 4.2%
2/26 QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2 3.9%
3/31 QIAGEN Receives U.S. FDA EUA for QIAstat-Dx test kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus 2.7%
12/26 Qiagen NV (NYSE: QGEN) had its "underperform" rating re-affirmed by analysts at Bank of America Corp. They now have a $28.00 price target on the stock. 11.0%
11/15 QIAGEN Receives Several Conditional, Non-binding Indications of Interest, Enters Into Discussions to Explore Potential Strategic Alternatives 8.5%
11/13 Qiagen up 7% on rumored Thermo Fisher interest [Seeking Alpha] 6.2%
10/9 Qiagen NV (NYSE: QGEN) was downgraded by analysts at Kepler Capital Markets from a "hold" rating to a "reduce" rating. 5.4%
1/8 Calibre Scientific Acquires NeXtal Biotechnologies to Further Expand its Protein Portfolio 5.3%
2/4 Q4/2019 12/31/2019 EPS 0.480 ZacksConsensus 0.440 ActVsEst 0.040 - Beat 5.1%
11/6 QIAGEN Launches Novel NGS Workflow for Simultaneous DNA and RNA Analysis for Use in Cancer Profiling at 2019 AMP Annual Meeting 4.2%
2/26 QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2 3.9%
3/31 QIAGEN Receives U.S. FDA EUA for QIAstat-Dx test kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus 2.7%
TOP News Decliners
10/7
QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests
-18.0%
5/6 Q1/2019 3/31/2019 EPS 0.270 ZacksConsensus 0.260 ActVsEst 0.010 - Beat -5.2%
3/11 Is This The Next Major Roadblock To The White House's Coronavirus Response? [zero hedge] -4.2%
7/24 Q2/2019 6/30/2019 EPS 0.330 ZacksConsensus N/A ActVsEst N/A - N/A -4.1%
11/18 Europe markets mostly higher as US-China trade talks dominate sentiment; Qiagen up 13% [CNBC] -3.2%
9/30 QIAGEN Launches Enhanced GeneGlobe Design & Analysis Hub, Combining Curated Knowledge, Content-based Assays and Analyses for Life Science Research -3.1%
2/5 Qiagen NV (NYSE: QGEN) had its "neutral" rating re-affirmed by analysts at Barclays PLC. -2.4%
3/18 Severe shortages of swabs and other supplies hamper testing [CNN] -2.2%
1/20 UPDATE 1-European shares dip as investors eye PMI data, ECB meeting [Reuters (UK)] -2.1%
8/20 Qiagen NV (NYSE: QGEN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -1.9%
5/6 Q1/2019 3/31/2019 EPS 0.270 ZacksConsensus 0.260 ActVsEst 0.010 - Beat -5.2%
3/11 Is This The Next Major Roadblock To The White House's Coronavirus Response? [zero hedge] -4.2%
7/24 Q2/2019 6/30/2019 EPS 0.330 ZacksConsensus N/A ActVsEst N/A - N/A -4.1%
11/18 Europe markets mostly higher as US-China trade talks dominate sentiment; Qiagen up 13% [CNBC] -3.2%
9/30 QIAGEN Launches Enhanced GeneGlobe Design & Analysis Hub, Combining Curated Knowledge, Content-based Assays and Analyses for Life Science Research -3.1%
2/5 Qiagen NV (NYSE: QGEN) had its "neutral" rating re-affirmed by analysts at Barclays PLC. -2.4%
3/18 Severe shortages of swabs and other supplies hamper testing [CNN] -2.2%
1/20 UPDATE 1-European shares dip as investors eye PMI data, ECB meeting [Reuters (UK)] -2.1%
8/20 Qiagen NV (NYSE: QGEN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -1.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: